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Abstract
 
The platelet glycoprotein (GP) Ib-IX-V complex mediates the attachment of platelets to the
blood vessel wall by binding von Willebrand factor (VWF), an interaction that also transmits
signals for platelet activation and aggregation. Because the complex is extensively palmitoy-
lated, a modification known to target proteins to lipid rafts, we investigated the role of raft lo-
calization in GP Ib-IX-V functions. In unstimulated platelets, a minor portion of the complex
localized to Triton-insoluble raft fractions; this portion increased three to sixfold with platelet
activation by VWF. Raft-associated GP Ib-IX-V was selectively palmitoylated, with GP Ib-
IX-V–associated palmitate increasing in the raft fraction on VWF-mediated activation. The raft
fraction was also the site of association between GP Ib-IX-V and the Fc receptor Fc
 
 
 
RIIA.
The importance of this association was demonstrated by the ability of the Fc
 
 
 
RIIA antibody
IV.3 to inhibit shear-induced platelet aggregation. Disruption of rafts by depleting membrane
cholesterol impaired several GP Ib-IX-V–dependent platelet fractions: aggregation to VWF
under static conditions and under shear stress, tyrosine phosphorylation, and adhesion to a
VWF surface. Partial restoration of membrane cholesterol content partially restored shear-
induced platelet aggregation and tyrosine phosphorylation. Thus, localization of the GP Ib-IX-V
complex within rafts is crucial for both platelet adhesion and postadhesion signaling.
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Introduction
 
When a blood vessel is injured, the first step in the hemo-
static or thrombotic response is adhesion of platelets to ex-
posed subendothelium. This reaction is mediated through
an interaction of the platelet glycoprotein (GP)
 
*
 
 Ib-IX-V
complex and subendothelial von Willebrand factor (VWF).
The GP Ib-IX-V complex comprises four transmembrane
polypeptide chains, GP Ib
 
 
 
, GP Ib
 
 
 
, GP IX, and GP V,
which are expressed on the platelet surface with a minimal
stoichiometry of 2:2:2:1, respectively (1). The VWF-bind-
ing site is contained within a globular region at the NH
 
2
 
terminus of GP Ib
 
 
 
 (for a review, see reference 1), the
largest subunit of the complex.
Though initially believed to be simply an adhesive inter-
action, there is now considerable evidence to indicate that
the binding of VWF to the GP Ib-IX-V complex results in
the inside-out activation of the integrin 
 
 
 
IIb
 
 
 
3
 
, and subse-
quent platelet aggregation (2–4). This receptor–ligand
interaction has been shown to initiate a number of trans-
membrane signaling events including cytoskeletal reorganiza-
tion (5), calcium mobilization (6), tyrosine phosphorylation
of platelet proteins (7, 8), activation of phosphoinositide
3-kinase (9) and protein kinase C, and the synthesis of
thromboxane A2 (5). However, the precise pathway of sig-
naling events induced by the GP Ib-IX-V–VWF interac-
tion has yet to be defined.
One interesting modification of the GP Ib-IX-V com-
plex that may provide a clue to its signaling function is the
thiol acylation of GP Ib
 
 
 
 and GP IX by palmitate (10).
Fatty acid modifications, such as palmitoylation, are be-
lieved to increase protein–lipid and protein–protein inter-
actions, and thus may facilitate signal transduction. Indeed,
palmitoylation has been shown to be important for protein
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signaling functions (11, 12) and localization of signaling
proteins to lipid rafts (12–15).
Lipid rafts (also known as GEMs, glycolipid-enriched
membranes; DRMs, detergent-resistant membranes; and
DIGs, detergent-insoluble glycolipid-rich domains) are dy-
namic assemblies of cholesterol and sphingolipids that are
more ordered in structure than the rest of the plasma mem-
brane (16). Rafts are specifically enriched in doubly ac-
ylated proteins such as the Src family kinases (17), trans-
membrane proteins modified by cysteine palmitoylation,
such as the adaptor linker of T cell activation (12) and gly-
cosylphosphatidylinositol-linked outer membrane proteins
(18). Lipid rafts are believed to act as platforms for signal
transduction by selectively attracting certain proteins while
excluding others (for reviews, see references 19–21). These
domains can be isolated from many cell types, including
hematopoietic cells, where they have been shown to play
critical roles in cell signaling (22–24).
Receptor clustering is an essential feature of signaling
through lipid rafts. The clustering of raft components has
been shown to result in the coalescence of the rafts (25),
thus connecting raft proteins and accessory molecules into a
larger domain, thereby facilitating signal transduction. In-
deed, antibody-mediated cross-linking of the T cell antigen
receptor (26) and Fc
 
 
 
RI (27) has been shown to result in
the aggregation of raft-associated proteins and in the initia-
tion of signaling cascades that lead to immune cell signal-
ing. Furthermore, cross-linking the raft component, gan-
glioside GM1, can also induce signaling (28).
Several lines of evidence have indicated that the cross-
linking of GP Ib-IX-V complexes by VWF initiates signal-
ing events that lead to platelet activation (29–33). Under-
standing signaling from the complex remains problematic,
however, as none of its component polypeptides contain
any of the classical domains involved in initiating signals.
Nevertheless, VWF-induced cross-linking of multiple GP
Ib-IX-V complexes may lead to receptor clustering, possi-
bly incorporating other receptors into the clusters, and
leading to their activation and the subsequent initiation of
signaling pathways. Consistent with this, the GP Ib-IX-V
complex has been shown to coimmunoprecipitate with
the immunoregulatory tyrosine activation motif–containing
proteins FcR 
 
 
 
-chain (34) and Fc
 
 
 
RIIA (35), and has been
demonstrated to be physically associated with the later (35,
36) on the platelet surface. The similarities between signal-
ing in immune cells through immune receptors and in
platelets through the GP Ib-IX-V complex are intriguing,
as is the fact that the complex is palmitoylated. Therefore,
we speculated that lipid rafts might play a key role in signal-
ing after engagement of the complex by VWF. Here, we
report on the association of the GP Ib-IX-V complex with
lipid rafts and present evidence for a physiological role for
this association in GP Ib-IX-V–mediated platelet function.
 
Materials and Methods
 
Materials.
 
The following mAbs, unlabeled and FITC-conju-
gated, were obtained from commercial sources: AK2 (anti-GP
 
Ib
 
 
 
; Research Diagnostics); IV.3 (anti-Fc
 
 
 
RIIA; Mederex);
4D10.1 (anti-Syk) and 4G10 (antiphosphotyrosine) were from
Upstate Biotechnology; SZ2 (anti-GP Ib
 
 
 
); and P2 (anti-
 
 
 
IIb
 
 
 
3
 
)
were purchased from Beckman Coulter. WM23 (anti-GP Ib
 
 
 
)
and purified human VWF were provided by M.C. Berndt (Baker
Medical Research Institute, Melbourne, Australia). Polyclonal an-
tisera generated against 
 
 
 
IIb
 
 
 
3
 
 and the mAb (AP3) against the 
 
 
 
3
 
integrin were provided by P. Thiagarajan (VA Medical Center,
Houston, TX) and P. Newman (Blood Research Institute, Mil-
waukee, WI), respectively. Rabbit anti–mouse IgG was from
Zymed Laboratories. Secondary antibody for immunoblotting and
chemiluminescence detection reagents were from Pierce Chemical
Co. Nitrocellulose was from Bio-Rad Laboratories. Pansorbin, a
suspension of heat-killed 
 
Staphylococcus aureus
 
 cells, was from Cal-
biochem. 
 
n
 
-Octyl 
 
 
 
-D-glucopyranoside was from Fisher Scien-
tific. [9,10-
 
3
 
H-(N)]palmitic acid was from Perkin Elmer Life Sci-
ence. Na
 
125
 
I was from ICN. Citrated porcine blood was provided
by M. Schreiber (Baylor College of Medicine, Houston, TX) and
plasma was obtained by sequential centrifugation as described be-
low for the isolation of human platelets. Methyl-
 
 
 
-cyclodextrin
(M
 
 
 
CD) and cholesterol-loaded M
 
 
 
CD were purchased from
Sigma-Aldrich, as were all other reagents unless otherwise stated.
 
Platelet Preparation.
 
Human blood was drawn from healthy,
medication-free, donors into 1/9 volume of 3.8% sodium citrate.
Platelet-rich plasma (PRP) was obtained by centrifugation (160 
 
g
 
,
20 min, 25
 
 
 
C). Platelets were obtained by subsequent centrifuga-
tion of the PRP (800 
 
g
 
, 12 min, 25
 
 
 
C) in the presence of 300
nM prostacyclin to prevent aggregation. If washed platelets were
desired, blood was collected into 1/6 volume of acid-citrate-
dextrose (85 mM trisodium citrate, 71 mM citric acid, and 111
mM dextrose). Platelets were obtained as described above, with
the omission of prostacyclin, and were washed by resuspension
in CGS buffer (13 mM sodium citrate, 30 mM glucose, and 120
mM NaCl), centrifuged again, and resuspended to their original
PRP volume in buffer 1 (134 mM NaCl, 12 mM NaHCO
 
3
 
, 2.9
mM KCl, 0.34 mM Na
 
2
 
HPO
 
4
 
, 1 mM MgCl
 
2
 
, 10 mM Hepes, 5
mM glucose, and 0.3 g/100 ml A; reference 37). To ensure that
observations were not restricted to an individual platelet donor,
all experiments were repeated several times using blood from dif-
ferent donors.
 
Platelet Lysis and Sucrose Density-Gradient Fractionation.
 
Plate-
lets (2–3 
 
 
 
 10
 
8
 
/ml; 4 ml) prepared as described above, were lysed
with 2 ml ice-cold Triton X-100 lysis buffer (25 mM MES, pH
6.5, 150 mM NaCl, 1% [wt/vol] Triton X-100, 10 mM benza-
midine, 1 mM PMSF, 20 
 
 
 
g/ml aprotinin, 20 
 
 
 
g/ml leupeptin,
and 100 
 
 
 
g/ml soybean trypsin inhibitor). All subsequent steps
were performed at 4
 
 
 
C. The lysate was adjusted to 40% (wt/vol)
sucrose by the addition of an equal volume of 80% (wt/vol) su-
crose in MES-buffered saline (25 mM MES, pH 6.5, 150 mM
NaCl). 4 ml of 30% sucrose, followed by 2 ml of 5% sucrose,
were gently layered over the 40% sucrose fraction in an ultracen-
trifuge tube. The samples were then centrifuged at 200,000 
 
g
 
 at
4
 
 
 
C for 18 h in a SW40 rotor (Beckman Coulter). 12 equal frac-
tions were collected from the top of the gradient.
 
Immunoprecipitation and Immunoblotting.
 
Equal volumes of
each fraction collected from the sucrose gradient were precleared
for 1 h at 4
 
 
 
C with Pansorbin. After removing the Pansorbin by
centrifugation, the samples were incubated overnight with pri-
mary antibodies and then immunoprecipitated with Pansorbin or
by the sequential addition of rabbit anti–mouse IgG and Pan-
sorbin when a primary mAb was used. The Pansorbin was pel-
leted by centrifugation, washed three times, and the bound
protein eluted by boiling in 2
 
 
 
 sample buffer containing 2% 
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-mercaptoethanol. Control immunoprecipitations were performed
with normal mouse IgG and/or rabbit anti–mouse IgG alone.
Immunoprecipitated proteins were resolved by 10% SDS-PAGE
under reducing conditions and transferred to nitrocellulose for
Western blotting/ECL. Dot blots were performed using a Bio-
Dot Microfiltration Apparatus (Bio-Rad Laboratories) according
to the manufacturer’s instructions and probed for ganglioside
GM1 with HRP-conjugated cholera toxin B subunit (10 
 
 
 
g/ml).
 
[
 
3
 
H]Palmitate Labeling of Platelet Proteins.
 
Washed platelets
were incubated at 37
 
 
 
C with 20 
 
 
 
Ci [9,10-
 
3
 
H-(N)]palmitic acid
for 45 min. Platelets were washed to remove unincorporated ra-
dioactivity and then activated with 10% (vol/vol) porcine plasma
(as a source of VWF). Platelets were pelleted, fractionated by su-
crose gradient centrifugation as described above. 
 
n
 
-Octyl 
 
 
 
-D-
glucopyranoside (60 mM) was added to each fraction to ensure
solubilization of the lipid rafts and associated proteins. The GP Ib
complex was immunoprecipitated (SZ2) from each fraction and
the associated radioactivity counted in a 
 
 
 
-counter.
 
Cholesterol Depletion and Repletion of Platelets.
 
To specifically
deplete the platelet membrane of cholesterol, PRP was incubated
with M
 
 
 
CD in buffer 1 at a final concentration of 10 mM (or
with an equal volume of buffer 1 as a control) for 30 min at 37
 
 
 
C.
The platelets were then used in subsequent experiments. For
cholesterol repletion studies, cholesterol-depleted platelets were
centrifuged and resuspended in buffer 1 containing 3 mM choles-
terol-loaded M
 
 
 
CD and incubated for 30 min at 37
 
 
 
C. Platelets
were centrifuged and resuspended in fresh platelet-poor plasma.
 
Platelet Aggregometry.
 
Platelet aggregation experiments using
PRP were performed with constant stirring at 1,200 rpm at 37
 
 
 
C
in a four-channel aggregometer (Biodata Corp.). After cholesterol
depletion of the platelets as described above, aggregation was ini-
tiated by the addition of either ristocetin (1 mg/ml) or 10% (vol/
vol) porcine plasma.
 
Shear-induced Platelet Aggregation.
 
Control or cholesterol-
depleted platelets (PRP; 500 
 
 
 
l) were loaded onto a cone–plate vis-
cometer (Rheostress 1 CS Rheometer; Haake) and sheared for 1
min at 10,000 1/s
 
.
 
 10 
 
 
 
l of sheared PRP was collected and fixed
in an isotonic solution containing 0.1% gluteraldehyde before
analysis. The extent of platelet aggregation was determined by
particle counting in a Coulter Counter (Coulter). The lower the
particle count, the greater the extent of aggregation. In studies
examining the contribution of Fc
 
 
 
RIIA to shear-induced platelet
aggregation, control platelets were incubated with 25 
 
 
 
g/ml of
IV.3, AK2, or abciximab for 10 min at room temperature before
shear. To study the effect of cholesterol depletion on shear-
induced tyrosine phosphorylation, washed, untreated, choles-
terol-depleted and cholesterol-depleted/repleted platelets were
subject to shear before lysis in 2
 
 
 
 sample buffer containing 2%
 
 
 
-mercaptoethanol and analysis by SDS-PAGE.
 
Platelet Adhesion Assays in a Parallel-Plate Flow Chamber.
 
Re-
combinant VWF A1 domain (amino acids 479–717; the domain
interacting with GP Ib
 
 
 
) was expressed and purified as described
previously (38). The protein (diluted to 150 
 
 
 
g/ml with TBS)
was immobilized onto glass coverslips by incubation at 37
 
 
 
C for
1 h. A coated coverslip was then incorporated into a parallel-plate
flow chamber (Glycotech) so that it formed the lower surface of
the chamber. The flow chamber was then mounted onto an in-
verted stage microscope (Eclipse TE300; Nikon Inc.) equipped
with an image recording system. PRP was incubated with M
 
 
 
CD
as described above before perfusion through the chamber at a flow
rate of 0.6 ml/min, generating a wall shear rate of 1,500 1/s.
 
Binding of 
 
125
 
I-labeled WM23 to Platelets.
 
The GP Ib
 
 
 
–spe-
cific mAb WM23 was iodinated using the Chloramine T method
 
(39) and separated from free label by gel filtration on Sephadex
G25. 
 
125
 
I-WM23 (10 
 
 
 
g/ml) was incubated with PRP for 20
min at room temperature; the platelets were then washed, resus-
pended with buffer 1, and either left untreated or activated with
10% (vol/vol) porcine plasma or 10 
 
 
 
M ADP. Lysis and sucrose
gradient fractionation was performed as above and the radioactiv-
ity associated with each fraction determined in a 
 
 
 
-counter.
 
Binding of 
 
125
 
I-labeled VWF to Platelets.
 
Untreated or choles-
terol-depleted washed platelets (final concentration 5 
 
 
 
 10
 
7
 
/ml, in
TBS/0.1% BSA) were incubated with increasing concentrations of
 
125
 
I-VWF (iodinated as for WM23) for 30 min at room tempera-
ture in the presence of ristocetin (1 mg/ml). The samples were
centrifuged at 20,000 
 
g
 
 for 2 min and the supernatant removed. The
radioactivity associated with the pellet was measured in a 
 
 
 
-counter.
Nonspecific binding was determined by including 10 
 
 
 
g/ml of
the inhibitory anti-GP Ib
 
 
 
 mAb AK2 in a parallel assay.
 
Flow Cytometry.
 
After treatment with M
 
 
 
CD, PRP (10 
 
 
 
l)
was incubated with 30 
 
 
 
l buffer 1 containing 10 
 
 
 
l of either
FITC-conjugated anti-GP Ib (SZ2) or anti-
 
 
 
IIb
 
 
 
3
 
 (P2) mAbs.
After a 20-min incubation at room temperature, the samples
were diluted 20-fold with PBS and analyzed in an EPICS XL
Coulter Flow Cytometer (Coulter). Background binding was de-
termined from parallel samples incubated with FITC-conjugated
mouse IgG.
 
Results
 
A Fraction of the GP Ib-IX-V Complex Resides within Lipid
Rafts.
 
Doharty et al. (40) described previously the pres-
ence of platelet GP Ib
 
 
 
 in rafts, but did not characterize
this further. Because of our interest in the signaling func-
tions of the GP Ib-IX-V complex, and because of the con-
spicuous presence of palmitate on two of its subunits, we
investigated the role of raft localization in GP Ib-IX-V
complex function. On sucrose density fractions of 1% Tri-
ton X-100 platelet lysates, a significant portion of the GP
Ib-IX-V complex could be found in the early fractions
(fractions 3–5), as determined by immunoprecipitation and
immunoblotting for GP Ib
 
 
 
 (Fig. 1 A, top). Upon platelet
activation with ristocetin/human VWF, the amount of GP
Ib-IX-V complex in these fractions increased approxi-
mately threefold (Fig. 1 A, middle). We confirmed that the
GP Ib-IX-V complex found in the early fractions was lo-
calized in lipid rafts by staining the fractions for the raft
marker ganglioside GM1, which also appeared predomi-
nantly in fractions 3–5 (Fig. 1 B, third panel). Concomitant
measurement of the total protein content of the fractions
indicates that fractions 3–5 contained only 1–2% of the to-
tal protein (unpublished data). The localization of the com-
plex in lipid rafts was not an artifact of Triton X-100 solu-
bilization, as we observed similar localization to raft
fractions when the platelets were lysed in two other non-
ionic detergents, Brij 58 and Brij 46 (unpublished data).
We also sought to confirm the increased localization of the
GP Ib-IX-V complex to the raft fraction upon VWF acti-
vation of platelets by other means. Therefore, we examined
the effect of platelet activation with porcine VWF on the
localization of an iodinated anti-GP Ib
 
 
 
 mAb. The anti-
body, WM23, binds within a mucin-like domain separat-
ing the ligand-binding domain from the plasma membrane 
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and does not affect ligand binding. The platelets were pre-
treated with 125I-labeled antibody, and lysed in their resting
state, or after activation with porcine VWF. Porcine VWF
is known to bind human GP Ib  without requiring modu-
lators or shear stress, and to activate platelets (41, 42). Fig. 1
B shows the fold changes in antibody-associated radioactiv-
ity as a consequence of platelet activation with either por-
cine VWF (top panel) or ADP (bottom panel). The
amount of radioactivity associated with the raft fractions in-
creased three to sixfold upon platelet activation with
porcine VWF and diminished correspondingly in the latter
fractions (Fig. 1 B, top). This increase occurred with plate-
let activation by VWF, but not in platelets activated with
ADP (Fig. 1 B, bottom).
To determine whether activation produced a general in-
crease in the raft localization of platelet adhesive receptors,
we also examined  IIb 3 distribution in the sucrose density
fractions from lysates of unstimulated platelets and platelets
activated with VWF. In unstimulated platelets, a small frac-
tion of the total  IIb 3 migrated in the early fractions (Fig.
1 C, top), but the quantity of  IIb 3 in these fractions did
not increase with VWF-induced platelet activation (Fig. 1
C, bottom).
Lipid Raft Associated GP Ib-IX-V Complex Is Palmitoy-
lated. Within the GP Ib-IX-V complex, both GP Ib  and
GP IX are palmitoylated at cysteinyl residues proximal to
the cytoplasmic face of the plasma membrane (10). Given
the proposed stoichiometry of the complex, in its minimal
conformation and fully palmitoylated state one would ex-
pect four palmitate moieties per complex, leading us to
consider that the complex may indeed localize to lipid rafts
through this fatty acyl modification. Therefore, we evalu-
ated whether the fraction of the GP Ib-IX-V complex re-
siding in rafts was selectively palmitoylated. Platelets were
labeled with [3H]palmitate before being lysed and fraction-
ated in a sucrose density gradient. The GP Ib-IX-V com-
plex was immunoprecipitated from each fraction, in the
presence of octyl- -glucopyranoside to exclude associated
palmitate-containing lipids, and the radioactivity of the im-
munoprecipitate was counted. Approximately half of the
total GP Ib-IX-V complex–associated palmitate in unstim-
ulated platelets was localized to the raft fractions (Fig. 2 A)
with the complex-associated palmitate being approximately
fourfold greater in fraction 4 than in fraction 10, a fraction
that contains approximately twice the absolute quantity of
GP Ib-IX-V in fraction 4 (Fig. 1 A). This result strongly
suggests that palmitoylation of the complex is responsible
for its partitioning to rafts. As expected, binding of porcine
VWF to the complex was associated with an increase in
palmitoylated GP Ib-IX-V complex in the raft fraction, but
not in nonraft fractions (Fig. 2 B).
Raft Disruption by Cholesterol Depletion Inhibits GP Ib-IX-
V–mediated Platelet Function. Then we investigated the
physiological significance of the partitioning of the GP Ib-
IX-V complex to lipid rafts. Membrane cholesterol deple-
tion is now an established method of disrupting lipid rafts
and raft-associated functions (20). In these studies, we se-
lectively depleted platelet membrane cholesterol using the
cholesterol-binding agent M CD (43). As a prelude to
functional studies, we examined the cholesterol removal by
M CD from platelets. 10 mM M CD efficiently removes
cholesterol from [3H]cholesterol-labeled platelets as a func-
tion of time, with  75% of the incorporated cholesterol
released after 30 min. Treatment of platelets with M CD
resulted in a complete loss of GP Ib-IX-V from the raft
fractions from the lipid raft fractions (Fig. 3 A).
Figure 1. The GP Ib-IX-V complex associates with
lipid rafts. (A) Unactivated or ristocetin/human VWF–
activated platelets were lysed with cold 1% Triton X-100.
Lysates were subjected to discontinuous sucrose gradient
centrifugation. Equal volume aliquots of each fraction
were immunoprecipitated using the anti-GP Ib  mAb
SZ2. Precipitated proteins were analyzed by reducing
SDS-PAGE followed by Western blot analysis with an
anti-GP Ib  mAb (WM23). Band intensities were quantitated by scanning densitometry. Blots represent seven independent experiments. The position of
the lipid rafts was identified by dot blotting of GM1 using HRP-conjugated cholera toxin B subunit as a probe. The lipid raft fraction floats within sucrose
gradient fractions 3–5. (B) Platelets, prelabeled with 125I-WM23, were left untreated or activated with either porcine VWF or ADP before being lysed and
subjected to sucrose gradient centrifugation. The data represent the fold-increase in radioactivity on VWF–induced platelet activation, compared with un-
activated platelets (n   3,  SEM). (C) Unactivated or porcine VWF-activated platelets were lysed and subjected to sucrose gradient centrifugation.
Equal-volume aliquots of each fraction were immunoprecipitated using polyclonal antisera against  IIb 3. Precipitated proteins were analyzed by reducing
SDS-PAGE followed by Western blot analysis with an anti- 3 integrin mAb (AP3). The blots are representative of three independent experiments.1061 Shrimpton et al.
Next we examined the effect of cholesterol depletion on
VWF-induced platelet aggregation, under both static con-
ditions and in the presence of shear stress. Aggregation in-
duced by ristocetin/human VWF or porcine VWF (Fig. 3
B) was inhibited by  70% by cholesterol depletion. More-
over, cholesterol depletion significantly inhibited shear-
induced aggregation (Fig. 3 C). The inhibitory effects of
cholesterol depletion were both time- and M CD dose–
dependent (unpublished data) with the inhibitory effect
correlating with the degree of cholesterol depletion. To
ensure that the results observed with cholesterol depletion
were not secondary to a nonspecific toxic effect of M CD
treatment, we performed control experiments in which we
partially reconstituted membrane cholesterol by treating
cholesterol-depleted platelets with cholesterol-loaded M CD.
Adding cholesterol back partially restored shear-induced
aggregation, albeit not to the levels seen before the platelets
were treated with M CD (Fig. 3 C).
These results suggested a role for lipid rafts in GP Ib-IX-V
signaling functions. We examined signaling function di-
rectly by determining the effect of cholesterol depletion
with M CD on tyrosine phosphorylation induced during
platelet activation with porcine VWF. M CD-treated
platelets demonstrated a marked delay in the time course of
phosphorylation of several proteins, among them the ty-
Figure 2. Raft-associated GP Ib-IX-V complex is selectively palmitoy-
lated. Unactivated or porcine VWF-activated [3H]palmitate-labeled plate-
lets were lysed with 1% Triton X-100. Lysates were subjected to discon-
tinuous sucrose gradient centrifugation. Equal-volume aliquots of each
fraction were immunoprecipitated using an anti-GP Ib  mAb (SZ2) and
the associated radioactivity counted in a  -counter. (A) Percentage of to-
tal GP Ib-associated [3H]palmitate by fraction from unactivated platelets
(n     5,   SEM). (B) Percentage change of total GP Ib–associated
[3H]palmitate upon activation in raft fractions (3–5) and nonraft fractions
(1–2, 6–12) (n   3,  SEM).
Figure 3. Cholesterol depletion results in the dissociation of the GP Ib-
IX-V complex from the lipid raft fraction and inhibits GP Ib-mediated
platelet activation. (A) Untreated or cholesterol-depleted platelets were
lysed and subjected to sucrose gradient centrifugation. Equal-volume ali-
quots of each fraction were immunoprecipitated using an anti-GP Ib 
mAb (SZ2). Precipitated proteins were analyzed by reducing SDS-PAGE
followed by Western blot analysis with an anti-GP Ib  mAb (WM23).
Blot is representative of five independent experiments. (B) Aggregation of
untreated or cholesterol-depleted platelets induced by ristocetin/human
VWF or porcine VWF. Aggregation was by conventional light aggre-
gometry. Data are representative of five independent experiments. (C)
Untreated, cholesterol-depleted, and cholesterol-depleted/repleted plate-
lets were sheared in a cone-plate viscometer for 60 s at 10,000 1/s. After
shear, an aliquot was fixed and the extent of platelet aggregation was de-
termined by particle counting in a Coulter counter. The data represent
the mean  SEM of triplicate samples from two independent experiments.1062 Role of Lipid Rafts in GP Ib-IX-V–Mediated Platelet Function
rosine kinase Syk, which has been implicated in the signal-
ing pathways activated by VWF binding to platelets (Fig. 4
A). We observed a similar effect of cholesterol depletion
on the phosphorylation of Syk associated with shear-
induced platelet aggregation (Fig. 4 B). As with aggrega-
tion, cholesterol repletion largely restored shear-induced
Syk phosphorylation.
The GP Ib-IX-V Complex Colocalizes with Fc RIIA in
Lipid Rafts. Several lines of evidence indicate that the
GP Ib-IX-V complex is physically and functionally associ-
ated with the immunoregulatory tyrosine activation mo-
tif–containing platelet Fc receptor Fc RIIA. Several dif-
ferent techniques have demonstrated that the receptors
physically associate (35, 36), and antibodies to either re-
ceptor can block the binding of ligands of the other (35,
44). In addition, Fc RIIA has been implicated in the
transmission of a portion of the signals generated on VWF
binding to the GP Ib-IX-V complex (44, 45). Given that
the complex is present in vast excess to Fc RIIA on the
platelet surface (1), we examined whether association of
the two receptors was confined to raft domains. We im-
munoprecipitated Fc RIIA from the sucrose gradient
fractions and evaluated the precipitate by immunoblotting
with the anti-GP Ib  mAb WM23 (Fig. 5 A). Association
of the two proteins occurred almost exclusively in the
rafts, supporting the hypothesis that GP Ib-IX-V induced
signal transduction may be mediated, at least in part, by
Fc RIIA. We observed no change in the extent of associ-
ation between the two proteins after platelet activation by
porcine VWF. Of interest, as with the GP Ib-IX-V com-
plex, only a portion of Fc RIIA resides in the raft fraction
(Fig. 5 A, bottom), but it is this fraction that contributes
virtually all of the Fc RIIA that associates with the GP
Ib-IX-V complex.
We also examined the functional implications of Fc-
 RIIA association with the GP Ib-IX-V complex in the
raft fractions by assessing the effect of the Fc RIIA mAb
IV.3 on shear-induced platelet aggregation. When prein-
cubated with a platelet suspension before shearing, IV.3
markedly inhibited shear-induced platelet aggregation
(60% inhibition), whereas a control antibody had no ef-
fect (Fig. 5 B). Aggregation was completely inhibited by
antibodies against either GP Ib  or the  IIb 3 complex, as
expected for a pathway involving first the binding of
VWF to GP Ib  and subsequent activation  IIb 3 and
platelet aggregation.
Figure 4. Cholesterol depletion results in decreased VWF-stimulated
tyrosine phosphorylation. (A) Washed untreated or cholesterol-depleted
platelets were sheared in a cone-plate viscometer for the indicated times
at 10,000 1/s before lysis and direct analysis of total protein tyrosine phos-
phorylation by SDS-PAGE and western with mAb 4G10. (B) Tyrosine
phosphorylation status of Syk before and after shear (60 s at 10,000 1/s) in
untreated, cholesterol-depleted or cholesterol-depleted/repleted platelets.
This figure is representative of three independent experiments
Figure 5. Colocalization of the GP Ib-X-V complex and Fc RIIA in
lipid rafts. (A) Unactivated platelets were lysed and subjected to sucrose
gradient centrifugation. Equal-volume aliquots of each fraction were
immunoprecipitated using an anti–Fc RIIA mAb (IV.3). Precipitated
proteins were analyzed by reducing SDS-PAGE followed by Western
blot analysis with WM23 (top). The distribution of total Fc RIIA across
the gradient was determined by dot blotting with IV.3 (bottom). Blots
represent three independent experiments. (B) PRP was preincubated
without antibody or with anti-Fc RIIA mAb (IV.3), anti-GP Ib mAb
(AK2), anti- IIb 3 (abciximab), or mouse IgG for 10 min before shearing
in a cone-plate viscometer for 60 s at 10,000 1/s. After shearing the sample,
an aliquot was fixed and the extent of platelet aggregation was determined
by particle counting using a Coulter counter (n   10, mean   SEM).1063 Shrimpton et al.
Cholesterol Depletion Markedly Inhibits GP Ib-IX-V–medi-
ated Adhesion of Platelets to a VWF Surface Under Conditions
of Flow. Also we investigated the effect of cholesterol de-
pletion on GP Ib-IX-V–mediated platelet adhesion to a
surface of immobilized VWF A1 under flow. We perfused
untreated or M CD-treated platelets over a matrix of puri-
fied recombinant VWF A1 domain, a fragment of VWF
containing the GP Ib  binding site and capable of support-
ing platelet adhesion (Fig. 6; reference 38). Use of the A1
domain allowed us to restrict our analysis to the effect of
cholesterol depletion on GP Ib-IX-V complex–mediated
platelet adhesion, as the A1 domain lacks binding sites for
other platelet adhesion receptors. Treatment of the platelets
with M CD markedly inhibited their ability to adhere to
the A1 surface at both high (1,500 1/s) and low (300 1/s)
shear stresses (unpublished data).
Cholesterol Depletion Alters Neither GP Ib-IX-V Complex
Conformation, Receptor Levels, nor the Binding of Soluble VWF
Under Static Conditions. To exclude the possibility that the
loss of platelet function observed after cholesterol depletion
was due to a conformational alteration in GP Ib-IX-V or
to its loss from the platelet surface, we assessed receptor
levels and VWF binding. The surface expression of the GP
Ib-IX-V complex and of the integrin  IIb 3 on cholesterol-
depleted platelets was determined by flow cytometry after
surface labeling of these receptors with FITC-conjugated
mAbs (Fig. 7 A). Surface levels of these receptors remained
unchanged after a 30-min treatment with 10 mM M CD.
In addition, the extent of ristocetin-induced binding of
125I-VWF, over a range of VWF concentrations, was
equivalent in the untreated and cholesterol-depleted plate-
let samples (Fig. 7 B).
Discussion
In this paper, we provide evidence for a role for lipid
rafts in GP Ib-IX-V–mediated platelet function. We have
demonstrated that a subset of the GP Ib-IX-V complex is
constitutively associated with lipid rafts in unstimulated
platelets and is further recruited to these membrane micro-
domains upon stimulation by VWF. By the techniques em-
ployed here, only a minor fraction of the complex localizes
to the raft fractions, but this fraction seems to have a crucial
role in the functions of the complex. Disruption of rafts by
cholesterol depletion markedly inhibited virtually every as-
pect of GP Ib-IX-V complex function, from its ability to
mediate platelet aggregation after binding VWF under
static conditions, to shear-induced platelet aggregation, to
its function in mediating platelet adhesion under flow. Im-
pairment of the former two functions appeared to involve
interference with the signaling functions of the complex, as
in both cases cholesterol depletion of platelets resulted in
diminished tyrosine phosphorylation (Fig. 4). Partial reple-
tion of platelet cholesterol restored both shear-induced
platelet aggregation (Fig. 3 C) and shear-induced phosphor-
ylation of the tyrosine kinase Syk (Fig. 4 B), a downstream
effector of GP Ib-IX-V–initiated signaling. It is difficult to
gauge whether the extent of restoration of platelet mem-
brane cholesterol was complete, but this is unlikely, possi-
bly accounting for the incomplete restoration of GP Ib-IX-V
functions. This would be consistent with our observation
that the effects of M CD treatment on platelet function
were dose and time-dependent (unpublished data). It is
also possible that extensive manipulation of the platelets
through the prolonged incubations required to first deplete
the cholesterol and then add it back may have itself blunted
their responsiveness.
As for the effect of cholesterol depletion on platelet ad-
hesion under conditions of flow, this effect appears to be
independent of GP Ib-IX-V complex signaling. The initial
step in platelet adhesion under high shear stresses involves
the tethering of the platelets to a VWF surface, which pre-
cedes any signals transmitted from the GP Ib-IX-V com-
plex. The GP Ib-IX-V–VWF interaction then allows the
platelets to decelerate by rolling, enabling the engagement
of other receptors that aid in the activation of the platelets
and their firm adhesion. In our studies of adhesion, we ex-
cluded participation of other receptors and therefore any
confounding effects of cholesterol depletion on these re-
ceptors by using the VWF A1 domain, which contains a
Figure 6. Cholesterol depletion inhibits
platelet adhesion to immobilized VWF-A1
domain. Glass coverslips were coated with
VWF A1 domain (150  g/ml) and perfused
with plasma containing untreated or choles-
terol-depleted platelets, at a shear rate of
1,500 1/s. The embossed micrographs rep-
resent five independent assays. Original
magnification: 400 .1064 Role of Lipid Rafts in GP Ib-IX-V–Mediated Platelet Function
binding site for GP Ib , but lacks the  IIb 3 binding site
present in mature VWF.
The fact that the initial adhesive event precedes the gen-
eration of intracellular signals is supported by the demon-
stration that polystyrene beads coated with the ligand-bind-
ing region of GP Ib  can tether under flow to a surface of
purified VWF (46). On platelets, however, the require-
ments for the complex to mediate adhesion are not as sim-
ple as merely the presence of the GP Ib  on the platelet
surface. The fact that raft disruption has such a profound ef-
fect on GP Ib-IX-V–mediated adhesion to VWF suggests
that the raft component of the complex has inherently dif-
ferent adhesive properties than the remaining complex
population, perhaps being organized into “adhesive patches”
on the surface that are required for efficient platelet capture
in flowing blood. Other adhesion receptors seem to func-
tion this way, their ability to mediate adhesion depending
on their localization to specific regions of the plasma mem-
branes of the cell on which they reside, although not nec-
essarily to rafts. The leukocyte adhesion receptors L-selec-
tin and PSGL-1, for example, both are found on the tips of
leukocyte microvilli, and their location in these regions has
been shown to facilitate their adhesive functions (47–49).
Platelets do not have microvilli, but the partitioning of a
subset of GP Ib-IX-V complexes to membrane micro-
domains may nevertheless facilitate adhesion. On possible
mechanism would be by localizing the complex to a region
of the membrane rich in signaling molecules that interact
with the cytoplasmic domains and affect the ability of the
extracellular portions to bind VWF.
Localization of the complex to lipid rafts appears to be a
function of cysteine palmitoylation, a modification that may
be dynamically regulated and thus amenable to pharmaco-
logical manipulation. Our studies showed that the raft frac-
tions were greatly enriched in GP Ib-IX-V–associated
palmitate, which increased with platelet activation (Fig. 2).
Our use of octyl- -glucopyranoside during the immuno-
precipitation procedure assured that the palmitate detected
was associated with protein, but as yet we do not have de-
finitive proof that the increase seen with VWF-mediated ac-
tivation corresponds to increased GP Ib-IX-V complex
palmitoylation. Another possibility is that other palmitoy-
lated proteins associate noncovalently with the complex on
VWF-mediated activation in a manner resistant to disrup-
tion by the detergents used. We are in the process of distin-
guishing between these two possibilities. If it turns out that
the increase in GP Ib-IX-V–associated palmitoylation results
from de novo attachment of palmitate to GP Ib  and GP IX
on VWF-induced platelet stimulation, this points to a role
for regulated palmitoylation in platelet function and suggests
the possibility that enzymatic acylation and deacylation of
the GP Ib-IX-V complex may regulate its association with
rafts and hence the VWF-induced platelet response.
These studies highlight a specific role for cholesterol in
platelet function and raise the possibility that plasma choles-
terol levels may modulate these functions. Consistent with
this, several studies have shown that the lipid environment
directly correlates with alterations in platelet cholesterol
and function (50, 51). Early studies by Shattil and col-
leagues (52) demonstrated that cholesterol loading of plate-
lets increased their reactivity to agonists and conversely,
that cholesterol depletion had an inhibitory effect. More
recent studies indicate that rafts are important in signaling
from the collagen receptor GP VI (53–55), in cold activa-
tion of platelets (56), and for localizing production of phos-
phoinositide 3-kinase products (57). Since raft size depends
on the concentration of sphingolipids and cholesterol in the
membrane (58), it leads us to consider that the platelet hy-
perreactivity observed in high cholesterol disease states,
such as hypercholesterolemia and atherosclerosis, may be
attributable to increased raft function.
Figure 7. Cholesterol depletion does not affect platelet receptor levels
or VWF binding. (A) The expression levels of the GP Ib-IX-V complex
and the integrin  IIb 3 were compared in untreated and cholesterol-
depleted washed platelets by staining with either FITC-conjugated anti-GP
Ib  (SZ2) or anti- IIb 3 (P2) mAbs. The fluorescence of each sample was
analyzed by flow cytometry (curves filled in black). The background fluo-
rescence was set with a FITC-conjugated mouse IgG (gray). The results
shown are representative of three separate experiments. (B) 125I-labeled
VWF was incubated with washed untreated and cholesterol-depleted
platelets in the presence of 1 mg/ml ristocetin. Specific binding was cal-
culated by subtracting nonspecific binding measured in the presence of
AK2, an antibody that blocks the GP Ib-VWF interaction. Data are ex-
pressed as the mean of triplicate samples ( SEM).1065 Shrimpton et al.
Thus, effects on platelet function via lipid rafts may be an
important consequence of alteration in plasma lipid levels
and could contribute to the morbidity associated with hy-
percholesterolemia, as well as being a salutary factor associ-
ated with lipid lowering.
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